Biogen reported its fourth-quarter and full-year 2025 financial results on February 6, 2026, signaling a definitive shift from a legacy company plagued by patent cliffs to a leaner, growth-oriented neurology powerhouse. The company has successfully traded volume for value, with full year 2025 revenue at $9.9 billion and improved underlying profitability as the company shed high-cost, low-margin legacy programs. By diversifying into rare diseases and Alzheimer's, the company has stabilized its floor.
Cyborg Score Rationale
Biogen maintains a robust gross margin of 75.24% and an operating margin of 24.75%, reflecting strong operational efficiency, with a healthy current ratio of 2.72 and a debt-to-equity ratio of 0.36, indicating solid liquidity and manageable debt levels. However, revenue is expected to decline by a mid-single-digit percentage for 2026 as compared to 2025 as further declines in multiple sclerosis product revenue are expected.
Top Insights
2025 performance reflected continued focus on strong execution and financial discipline, driven by revenue of nearly $1 billion from LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, and resilience of the MS franchise.
Global in-market sales for Leqembi reached $134 million in Q4 2025, a 54% increase compared to the same period in 2024, allowing Biogen to maintain a dominant 60% share of the anti-amyloid market.
The May 24, 2026 decision date for the Leqembi subcutaneous autoinjector would allow patients to initiate treatment with a simple injection at home rather than a bi-weekly infusion at a clinic, which could drastically lower the barrier to entry and accelerate market penetration.
The global rise in neurodegenerative diseases as the 'Baby Boomer' generation ages provides a massive, growing TAM (Total Addressable Market) for Biogen's offerings.
Named Competitors
Aducanumab — Alzheimer's treatment (withdrawn due to controversy)
Leqembi — Leading anti-amyloid Alzheimer's therapy
Kisunla — Competing anti-amyloid Alzheimer's drug
Multiple Sclerosis Portfolio — Next-generation MS therapies and oral generics
Recent Developments
(February 2026) Biogen reported Q4 2025 earnings beat with $2.3B revenue, exceeding expectations and raising 2026 guidance
(February 2026) FDA granted Priority Review for LEQEMBI IQLIK initiation and Breakthrough Therapy Designation for litifilimab in cutaneous lupus
(February 2026) Full year 2025 revenue reached $9.9B with 2% growth; growth products revenue rose 19%
Open the full interactive Biogen Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.